Tag Archives: QURE
Tuesday’s Midday Movers: NovaBay Pharma (NBY), Anthera Pharmaceuticals (ANTH), uniQure NV (QURE), Fuelcell Energy (FCEL), Organovo Holdings (ONVO)
So far Tuesday, June 11, NASDAQ is down -3.19% and the S&P is down -2.4%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; NovaBay Pharma (NBY – Research Report), Anthera Pharmaceuticals (ANTH –
Tuesday’s Midday Stock Update: NovaBay Pharma (NBY), Anthera Pharmaceuticals (ANTH), uniQure NV (QURE), Fuelcell Energy (FCEL), Organovo Holdings (ONVO)
So far Tuesday, June 11, NASDAQ is down -3.19% and the S&P is down -2.41%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; NovaBay Pharma (NBY – Research Report), Anthera Pharmaceuticals (ANTH –
Cantor Fitzgerald Believes uniQure NV (NASDAQ: QURE) Won’t Stop Here
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on uniQure NV (QURE – Research Report) today and set a price target of $81. The company’s shares opened today at $57.55, close to its 52-week high of $60.95. Piros observed:
Analysts Are Bullish on These Healthcare Stocks: uniQure NV (QURE), Insmed (INSM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on uniQure NV (QURE – Research Report) and Insmed (INSM – Research Report) with bullish sentiments. uniQure NV (QURE) H.C. Wainwright analyst Debjit
uniQure NV (QURE) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on uniQure NV (QURE – Research Report) today and set a price target of $68. The company’s shares closed yesterday at $33.18. Piros commented: “: We reiterate our Overweight rating and
Chardan Capital Reaffirms Their Buy Rating on uniQure NV (QURE)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on uniQure NV (QURE – Research Report), with a price target of $70. The company’s shares opened today at $30.12. According to TipRanks.com, Amusa is a
